Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Crizotinib

FDA-approved product (capsule, oral), marketed as Xalkori.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Crizotinib
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cancer
  • Neoplasm
  • Non-small cell lung carcinoma

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Anaplastic lymphoma kinase (alk) inhibitors
FDA pharmacologic class
Kinase Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA62.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli52.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae27.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis62.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Crizotinib in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.3 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.4 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.7 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.7 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Crizotinib with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has Progressed

    NCT02761057 · start 2016-07-25

    Registered record
    Registry ID
    NCT02761057
    Conditions
    Locally Advanced Papillary Renal Cell Carcinoma; Metastatic Papillary Renal Cell Carcinoma; Stage III Renal Cell Cancer AJCC v7; Stage IV Renal Cell Cancer AJCC v7; Type 1 Papillary Renal Cell Carcinoma; Type 2 Papillary Renal Cell Carcinoma; Unresectable Renal Cell Carcinoma
    Interventions
    Biospecimen Collection; Bone Scan; Cabozantinib S-malate; Computed Tomography; Crizotinib; Savolitinib; Sunitinib Malate
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2016-07-25
    Completion
    2023-10-19
    Enrolment
    152

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLocally Advanced Papillary Renal Cell Carcinoma; Metastatic Papillary Renal Cell Carcinoma; Stage III Renal Cell Cancer AJCC v7; Stage IV Renal Cell Cancer AJCC v7 +3 more
    InterventionBiospecimen Collection; Bone Scan; Cabozantinib S-malate; Computed Tomography +3 more
    PhasePhase 2
    Registry statusCompleted

  • Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Exon 14 Deletion Genetic Changes (MATCH - Subprotocol C2)

    NCT06360575 · start 2016-07-20

    Registered record
    Registry ID
    NCT06360575
    Conditions
    Advanced Lymphoma; Advanced Malignant Solid Neoplasm; Refractory Lymphoma; Refractory Malignant Solid Neoplasm; Refractory Multiple Myeloma
    Interventions
    Biopsy Procedure; Biospecimen Collection; Crizotinib; Radiologic Examination
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2016-07-20
    Completion
    2026-12-31
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Lymphoma; Advanced Malignant Solid Neoplasm; Refractory Lymphoma; Refractory Malignant Solid Neoplasm +1 more
    InterventionBiopsy Procedure; Biospecimen Collection; Crizotinib; Radiologic Examination
    PhasePhase 2
    Registry statusActive not recruiting

  • Molecularly Target Therapy With GEMOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma

    NCT02836847 · start 2016-07

    Registered record
    Registry ID
    NCT02836847
    Conditions
    Cholangiocarcinoma of the Extrahepatic Bile Duct; Gallbladder Cancer
    Interventions
    biological test; GEMOX; Cetuximab; Trastuzumab; Gefitinib; Lapatinib; Everolimus; Sorafenib; Crizotinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2016-07
    Completion
    2020-12
    Enrolment
    152

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCholangiocarcinoma of the Extrahepatic Bile Duct; Gallbladder Cancer
    Interventionbiological test; GEMOX; Cetuximab; Trastuzumab +5 more
    PhasePhase 2
    Registry statusUnknown

  • ALTA-1L Study: A Study of Brigatinib Versus Crizotinib in Anaplastic Lymphoma Kinase Positive (ALK+) Advanced Non-small Cell Lung Cancer (NSCLC) Participants

    NCT02737501 · start 2016-05-26

    Registered record
    Registry ID
    NCT02737501
    Conditions
    Non-small Cell Lung Cancer; Lung Cancer; Advanced Malignancies; Carcinoma
    Interventions
    Brigatinib; Crizotinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2016-05-26
    Completion
    2021-01-29
    Enrolment
    275

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-small Cell Lung Cancer; Lung Cancer; Advanced Malignancies; Carcinoma
    InterventionBrigatinib; Crizotinib
    PhasePhase 3
    Registry statusCompleted

  • Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)

    NCT02568267 · start 2015-11-19

    Registered record
    Registry ID
    NCT02568267
    Conditions
    Breast Cancer; Cholangiocarcinoma; Colorectal Cancer; Head and Neck Neoplasms; Lymphoma, Large-Cell, Anaplastic; Melanoma; Neuroendocrine Tumors; Non-Small Cell Lung Cancer; Ovarian Cancer; Pancreatic Cancer; Papillary Thyroid Cancer; Primary Brain Tumors; Renal Cell Carcinoma; Sarcomas; Salivary Gland Cancers; Adult Solid Tumor
    Interventions
    Entrectinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2015-11-19
    Completion
    2027-06-30
    Enrolment
    534

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer; Cholangiocarcinoma; Colorectal Cancer; Head and Neck Neoplasms +12 more
    InterventionEntrectinib
    PhasePhase 2
    Registry statusActive not recruiting

  • Alectinib Versus Pemetrexed or Docetaxel in Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) Participants Previously Treated With Platinum-Based Chemotherapy and Crizotinib

    NCT02604342 · start 2015-11-03

    Registered record
    Registry ID
    NCT02604342
    Conditions
    Non-small Cell Lung Cancer
    Interventions
    Alectinib; Docetaxel; Pemetrexed
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2015-11-03
    Completion
    2018-08-13
    Enrolment
    119

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-small Cell Lung Cancer
    InterventionAlectinib; Docetaxel; Pemetrexed
    PhasePhase 3
    Registry statusCompleted

  • Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

    NCT02465060 · start 2015-08-17

    Registered record
    Registry ID
    NCT02465060
    Conditions
    Advanced Lymphoma; Advanced Malignant Solid Neoplasm; Bladder Carcinoma; Breast Carcinoma; Cervical Carcinoma; Colon Carcinoma; Colorectal Carcinoma; Endometrial Carcinoma; Esophageal Carcinoma; Exocrine Pancreas Carcinoma; Gastric Carcinoma; Glioma; Head and Neck Carcinoma; Hematopoietic and Lymphoid Cell Neoplasm; Kidney Carcinoma; Liver Carcinoma; Lung Carcinoma; Lymphoma; Malignant Uterine Corpus Neoplasm; Malignant Uterine Neoplasm; Melanoma; Multiple Myeloma; Ovarian Carcinoma; Prostate Carcinoma; Rectal Carcinoma; Recurrent Bladder Carcinoma; Recurrent Breast Carcinoma; Recurrent Cervical Carcinoma; Recurrent Colon Carcinoma; Recurrent Colorectal Carcinoma; Recurrent Esophageal Carcinoma; Recurrent Gastric Carcinoma; Recurrent Glioma; Recurrent Head and Neck Carcinoma; Recurrent Liver Carcinoma; Recurrent Lung Carcinoma; Recurrent Lymphoma; Recurrent Malignant Solid Neoplasm; Recurrent Malignant Uterine Corpus Neoplasm; Recurrent Melanoma; Recurrent Multiple Myeloma; Recurrent O
    Interventions
    Adavosertib; Afatinib; Afatinib Dimaleate; Binimetinib; Biopsy Procedure; Biospecimen Collection; Capivasertib; Computed Tomography; Copanlisib; Copanlisib Hydrochloride; Crizotinib; Cytology Specimen Collection Procedure; Dabrafenib; Dabrafenib Mesylate; Dasatinib; Defactinib; Defactinib Hydrochloride; Echocardiography Test; Erdafitinib; Fexagratinib; Ipatasertib; Laboratory Biomarker Analysis; Larotrectinib; Larotrectinib Sulfate; Magnetic Resonance Imaging; Multigated Acquisition Scan; Nivolumab; Osimertinib; Palbociclib; Pertuzumab; PI3K-beta Inhibitor GSK2636771; Radiologic Examination; Radionuclide Imaging; Relatlimab; Sapanisertib; Sunitinib Malate; Taselisib; Trametinib; Trastuzumab; Trastuzumab Emtansine; Ulixertinib; Vismodegib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2015-08-17
    Completion
    2026-12-31
    Enrolment
    6,452

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Lymphoma; Advanced Malignant Solid Neoplasm; Bladder Carcinoma; Breast Carcinoma +38 more
    InterventionAdavosertib; Afatinib; Afatinib Dimaleate; Binimetinib +38 more
    PhasePhase 2
    Registry statusActive not recruiting

  • Testing Crizotinib as a Potential Targeted Treatment in Cancers With ROS1 Genetic Changes (MATCH-Subprotocol G)

    NCT04439253 · start 2015-08-12

    Registered record
    Registry ID
    NCT04439253
    Conditions
    Advanced Lymphoma; Advanced Malignant Solid Neoplasm; Hematopoietic and Lymphoid Cell Neoplasm; Refractory Lymphoma; Refractory Malignant Solid Neoplasm; Refractory Multiple Myeloma
    Interventions
    Crizotinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2015-08-12
    Completion
    2027-03-17
    Enrolment
    4

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Lymphoma; Advanced Malignant Solid Neoplasm; Hematopoietic and Lymphoid Cell Neoplasm; Refractory Lymphoma +2 more
    InterventionCrizotinib
    PhasePhase 2
    Registry statusActive not recruiting

  • Testing Crizotinib as a Potential Targeted Treatment in Cancers With ALK Genetic Changes (MATCH-Subprotocol F)

    NCT04439266 · start 2015-08-12

    Registered record
    Registry ID
    NCT04439266
    Conditions
    Advanced Lymphoma; Advanced Malignant Solid Neoplasm; Hematopoietic and Lymphoid Cell Neoplasm; Refractory Lymphoma; Refractory Malignant Solid Neoplasm; Refractory Multiple Myeloma
    Interventions
    Crizotinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2015-08-12
    Completion
    2027-03-30
    Enrolment
    5

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Lymphoma; Advanced Malignant Solid Neoplasm; Hematopoietic and Lymphoid Cell Neoplasm; Refractory Lymphoma +2 more
    InterventionCrizotinib
    PhasePhase 2
    Registry statusActive not recruiting

  • A Phase II Study to Evaluate the Efficacy and Safety of Oral Ceritinib in Patients With ALK-positive NSCLC Metastatic to the Brain and/or to Leptomeninges

    NCT02336451 · start 2015-04-01

    Registered record
    Registry ID
    NCT02336451
    Conditions
    ALK-positive Non-small Cell Lung Cancer
    Interventions
    Ceritinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2015-04-01
    Completion
    2019-02-06
    Enrolment
    156

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionALK-positive Non-small Cell Lung Cancer
    InterventionCeritinib
    PhasePhase 2
    Registry statusCompleted

  • Crizotinib in High-Risk Uveal Melanoma Following Definitive Therapy

    NCT02223819 · start 2015-03

    Registered record
    Registry ID
    NCT02223819
    Conditions
    Uveal Melanoma
    Interventions
    Crizotinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2015-03
    Completion
    2019-07-03
    Enrolment
    34

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUveal Melanoma
    InterventionCrizotinib
    PhasePhase 2
    Registry statusCompleted

  • Crizotinib in Pretreated Metastatic Non-small-cell Lung Cancer With MET Amplification or ROS1 Translocation (METROS)

    NCT02499614 · start 2014-12

    Registered record
    Registry ID
    NCT02499614
    Conditions
    Carcinoma, Non-Small-Cell Lung
    Interventions
    Crizotinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2014-12
    Completion
    2018-12
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCarcinoma, Non-Small-Cell Lung
    InterventionCrizotinib
    PhasePhase 2
    Registry statusUnknown

  • A Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer Participants

    NCT02075840 · start 2014-08-19

    Registered record
    Registry ID
    NCT02075840
    Conditions
    Non-Small Cell Lung Cancer
    Interventions
    Alectinib; Crizotinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2014-08-19
    Completion
    2025-04-28
    Enrolment
    303

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-Small Cell Lung Cancer
    InterventionAlectinib; Crizotinib
    PhasePhase 3
    Registry statusCompleted

  • A Clinical Study Testing The Safety And Efficacy Of Crizotinib In East Asian Patients With Anaplastic Lymphoma Kinase (ALK) Positive Advanced Non-Small Cell Lung Cancer

    NCT01500824 · start 2014-05

    Registered record
    Registry ID
    NCT01500824
    Conditions
    Non-Small Cell Lung Cancer
    Interventions
    Crizotinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Withdrawn
    Start
    2014-05
    Completion
    2016-05
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-Small Cell Lung Cancer
    InterventionCrizotinib
    PhasePhase 2
    Registry statusWithdrawn

  • N-of-1 Trial: Actionable Target Identification in Metastatic Cancer for Palliative Systemic Therapy

    NCT02142036 · start 2014-05

    Registered record
    Registry ID
    NCT02142036
    Conditions
    Metastatic Cancer
    Interventions
    EMA-approved ATI based targeted therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2014-05
    Completion
    2018-08
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Cancer
    InterventionEMA-approved ATI based targeted therapy
    PhasePhase 2
    Registry statusCompleted